Of note, several studies have demonstrated that dual PPARα and PPARγ agonists are effective for treatment of metabolic diseases including NAFLD in ob/ob mice and rats (34, 56). Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.